ReviewiScience2022
Understanding flow chemistry for the production of active pharmaceutical ingredients.
Review in iScience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Geminal Difunctionalization of Ketones via C─S Bond Insertion of Photogenerated Donor-Donor Diazo Compounds.Angewandte Chemie (International ed. in English) · 2026Article
- Merging Biocatalysis and Chemocatalysis in Flow: State-of-the-Art and Future Directions for Sustainable Synthesis.Angewandte Chemie (International ed. in English) · 2026Review
- Review
- Advances in solid handling for continuous flow synthesis of specialty chemicals and pharmaceuticals.Communications chemistry · 2026Review
- Advances in Flow Chemistry for Organolithium-Based Synthesis: A Process Perspective.Molecules (Basel, Switzerland) · 2025Review
- Photoactive PFA Coating through Fluorophilic Interactions for Continuous Flow Photochemistry.JACS Au · 2025Article
- A continuous flow process for the Ireland-Claisen rearrangement.RSC advances · 2025Article
- Flow chemistry-enabled asymmetric synthesis of cyproterone acetate in a chemo-biocatalytic approach.Nature communications · 2025Article
- Poly(ADP-Ribose) Polymerase (PARP) Inhibitors for Cancer Therapy: Advances, Challenges, and Future Directions.Biomolecules · 2024Review
- Article
- From Batch to the Semi-Continuous Flow Hydrogenation ofPharmaceutics · 2023Article
- Process Intensification of a Napabucasin Manufacturing Method Utilizing Microflow Chemistry.ACS omega · 2023Article
- Towards Antibiotic Synthesis in Continuous-Flow Processes.Molecules (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multi-step organic syntheses of various drugs, active pharmaceutical ingredients, and other pharmaceutically and agriculturally important compounds have already been reported using flow synthesis. Compared to batch, hazardous and reactive reagents can be handled safely in flow. This review discusses the pros and cons of flow chemistry in today's scenario and recent developments in flow devices. The review majorly emphasizes on the recent developments in the flow synthesis of pharmaceutically important products in last five years including flibanserin, imatinib, buclizine, cinnarizine, cyclizine, meclizine, ribociclib, celecoxib, SC-560 and mavacoxib, efavirenz, fluconazole, melitracen HCl, rasagiline, tamsulosin, valsartan, and hydroxychloroquine. Critical steps and new development in the flow synthesis of selected compounds are also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.